Cat. No.: HY-15713

Copy Link Print Information

NMS-873

19 Cited Publications

Customer Review

Based on 19 publication(s) in Google Scholar

NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC₅₀ value of 30 nM.

For research use only. We do not sell to patients.

Purity: 99.92%
CAS No.: 1418013-75-8
Formula: C₂₇H₂₈N₄O₃S₂
Molecular Weight:520.67

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

NMS-873 Chemical Structure

CAS No.: 1418013-75-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (19)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC₅₀ value of 30 nM.

IC₅₀ & Target

IC50: 30 nM^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
BTI-TN-5B1-4	IC₅₀	0.024 μM Compound: 116	Inhibition of human recombinant His-GST tagged VCP expressed in baculovirus infected Hi5 cells assessed as ADP formation incubated for 20 mins proir to substrate addition measured after 90 mins by NADH coupled assay Inhibition of human recombinant His-GST tagged VCP expressed in baculovirus infected Hi5 cells assessed as ADP formation incubated for 20 mins proir to substrate addition measured after 90 mins by NADH coupled assay	[PMID: 23245311]
HCT-116	IC₅₀	0.38 μM Compound: 116	Cytotoxicity against human HCT116 cells after 72 hrs by luciferase reporter gene assay Cytotoxicity against human HCT116 cells after 72 hrs by luciferase reporter gene assay	[PMID: 23245311]
HCT-116	IC₅₀	0.45 μM Compound: 32; NMS-873	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability	[PMID: 36893622]
L929	IC₅₀	1.3 nM Compound: 32; NMS-873	Antiproliferative activity against mouse L929 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay Antiproliferative activity against mouse L929 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay	[PMID: 36893622]
U-87MG ATCC	IC₅₀	6214.67 nM Compound: NMS-873	Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by cell titer-glo luminescent assay	[PMID: 36634454]

In Vitro

NMS-873 has antiproliferative effect on a panel of tumor cell lines with IC₅₀ values in the range of 0.08 μM to 2 μM. For HCT116 and HeLa cells, the IC₅₀ values are 0.4 μM and 0.7 μM, respectively. NMS-873 reduces VCP sensitivity to trypsin digestion, preventing degradation of the linker-D2 domain. NMS-873 induces clear, dose-dependent accumulation of poly-Ub proteins and stabilization of cyclin E and Mcl-1 at doses consistent with its antiproliferative IC₅₀ value^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1418013-75-8
Appearance Solid
Molecular Weight 520.67
Formula C₂₇H₂₈N₄O₃S₂
Color Off-white to yellow
SMILES

CC(C=C(OCC1=NN=C(SC2CCCC2)N1C3=CC=CN=C3)C=C4)=C4C5=CC=C(S(=O)(C)=O)C=C5
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (19)

All Cell Imaging/StainingWB

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

VCP downstream metabolite glycerol-3-phosphate (G3P) inhibits CD8+T cells function in the HCC microenvironment. [Abstract]

2025 Jan 24;10(1):26. PMID: 39848960

NMS-873 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Jan 24;10(1):26. [Abstract]

Immunoblot analysis of the indicated proteins in HCCLM3 cells treated with gradient concentrations of NMS-873 (4-8 μM) or Vehicle for 18h.
Mol Cell

RNF126-Mediated Reubiquitination Is Required for Proteasomal Degradation of p97-Extracted Membrane Proteins. [Abstract]

2020 Jul 16;79(2):320-331.e9. PMID: 32645369

NMS-873 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2020 Jul 16;79(2):320-331.e9. [Abstract]

Inhibition of E1 activity impairs degradation of retrotranslocated ABCG2-F208S. Cells expressing FLAG-tagged ABCG2-F208S and myc-tagged ubiquitin were pretreated for 1 h with NMS-873 (10 μM) and z-VAD (60 μM) and then chased with z-VAD, CHX, and either MG132 (20 μM) or MLN7243 (10 μM). The cells were semipermeabilized at 0 and 2 h with digitonin. The cytosolic and membrane fractions were analyzed by immunoblotting for indicated proteins either directly or after anti-FLAG immunoprecipitations (IPs). Arrowheads denote glycosylated ABCG2-F208S extracted from the ER. Samples IPed from the cytosolic fraction were either left untreated or digested with the endoglycosidase H (bottom)
Neuron

Polyserine-mediated targeting of FAF2/UBXD8 ameliorates tau aggregation. [Abstract]

2025 Aug 29:S0896-6273(25)00587-2. PMID: 40902597
J Immunother Cancer

Targeting VCP enhances colorectal cancer therapy through STING stabilization. [Abstract]

2025 Nov 19;13(11):e012652. PMID: 41260904
Phytomedicine

Self-assembly of glycyrrhizic acid and aconitine alleviates heart failure by inhibiting autophagy and inducing reprogramming of energy metabolism. [Abstract]

2026 Jun:155:158094. PMID: 41886950
EMBO Mol Med

Sigma-1 receptor attenuates osteoclastogenesis by promoting ER-associated degradation of SERCA2. [Abstract]

2022 Jul 7;14(7):e15373. PMID: 35611810

NMS-873 purchased from MedChemExpress. Usage Cited in: EMBO Mol Med. 2022 Jul 7;14(7):e15373. [Abstract]

Western blots showing SERCA2 expression in HEK‐293T cells with or without Sigmar1 co‐transfection treated with NMS‐873 (0.25-1 μM) at the indicated concentration. All inhibitors were applied to cells 8 h prior to protein collection.
Biomed Pharmacother

TME-responsive nanoparticles co-targeting VCP, NETs, and dual immune checkpoints for immune revitalization in EGFR/PD-L1/CTLA-4-driven colorectal cancer. [Abstract]

2025 Sep 18:192:118565. PMID: 40972397
Cell Chem Biol

6-Phosphogluconate Dehydrogenase Links Cytosolic Carbohydrate Metabolism to Protein Secretion via Modulation of Glutathione Levels. [Abstract]

2019 Sep 19;26(9):1306-1314.e5. PMID: 31204288

NMS-873 purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2019 Sep 19;26(9):1306-1314.e5. [Abstract]

Representative WM793 cells using (A) light microscopy and (B) electron microscopy. The treatments include brefeldin A (1 μM, 36 h), 6AN (20 μM, 48 h), and NMS-873 (5 μM, 18 h).

NMS-873 purchased from MedChemExpress. Usage Cited in: Cell Chem Biol. 2019 Sep 19;26(9):1306-1314.e5. [Abstract]

Immunoblots of HSPA5 (Bip) and spliced XBP1 (XBP1s) in WM793 cells treated with brefeldin A (1 μM, 36h), 6AN (20 μM, 48h), or NMS873 (5 μM, 18h).
Cell Rep

Translocational attenuation mediated by the PERK-SRP14 axis is a protective mechanism of unfolded protein response. [Abstract]

2024 Jun 27;43(7):114402. PMID: 38943644
Inflammation

VCP Inhibition Augments NLRP3 Inflammasome Activation. [Abstract]

2024 Oct;47(5):1868-1883. PMID: 38563877
Cell Oncol (Dordr)

Targeting VCP with V8 suppresses glioblastoma development via formation of aggregates and disruption of mitophagy flux. [Abstract]

2026 Jan 8;49(1):21. PMID: 41505038
FASEB J

FAT1 Enhances the Sensitivity of Non-Small Cell Lung Cancer to VCP Inhibitors by Regulating the Activation of the Endoplasmic Reticulum Stress Pathway. [Abstract]

2025 May 15;39(9):e70585. PMID: 40293794
J Cell Mol Med

p97/VCP promotes Cullin-RING-ubiquitin-ligase/proteasome-dependent degradation of IκBα and the preceding liberation of RelA from ubiquitinated IκBα. [Abstract]

2016 Jan;20(1):58-70. PMID: 26463447

NMS-873 purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2016 Jan;20(1):58-70. [Abstract]

Efficient TNF-induced degradation of IκBα and concomitant liberation of RelA requires functional p97/VCP. Cells stimulated with TNF (10 ng/mL) for the indicated times after either pretreatment with p97/VCP inhibitor NMS-873 (2.5 μM, NMS³) for 10 min. or inhibitor treatment (2.5 μM) from 15 min. after stimulation in either the presence (NMS¹) or the absence (NMS²) of pan-caspase inhibitor ZVAD-fmk (10 μM), are subjected to subcellular fractionation. LMB (10 ng/mL)
J Biol Chem

AAA-ATPase valosin-containing protein binds the transcription factor SREBP1 and promotes its proteolytic activation by rhomboid protease RHBDL4. [Abstract]

2022 Jun;298(6):101936. PMID: 35430252
Vet Microbiol

Valosin-containing protein (VCP/p97) is responsible for the endocytotic trafficking of classical swine fever virus. [Abstract]

2022 Sep:272:109511. PMID: 35849988
bioRxiv

2026 Mar 13.
bioRxiv

Nuclear tau aggregates inhibit RNA export and form by secondary seeding from cytosolic tau aggregates. [Abstract]

2026 Feb 18:2026.02.17.706203. PMID: 41756918
bioRxiv

2024 June 12.
bioRxiv

VCP increases or decreases tau seeding using specific cofactors. [Abstract]

2023 Aug 30:2023.08.30.555637. PMID: 37693404

Solvent & Solubility

In Vitro:

DMSO : 20.5 mg/mL (39.37 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9206 mL

9.6030 mL

19.2060 mL

5 mM

0.3841 mL

1.9206 mL

3.8412 mL

10 mM

0.1921 mL

0.9603 mL

1.9206 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

The ATPase activity and the kinetic parameters of recombinant wild-type VCP and its mutants are evaluated by monitoring ADP formation in the reaction, using a modified NADH-coupled assay46. As ADP and NADH are ATP-competitive inhibitors of VCP ATPase activity, the standard protocol for the NADH-coupled assay is modified into a two-step procedure. In the first part, an ATP-regenerating system (40 U/mL pyruvate kinase and 3 mM phosphoenolpyruvate) recycles the ADP produced by VCP activity, keeps the substrate concentration constant (thus preventing product inhibition) and accumulates a stoichiometric amount of pyruvate. In the second part, the VCP enzymatic reaction is quenched with 30 mM EDTA and 250 μM NADH and stoichiometrically oxidized by 40 U/mL lactic dehydrogenase to reduce accumulated pyruvate. The decrease of NADH concentration is measured at 340 nm using a Tecan Safire 2 reader plate. The assay is performed in 96- or 384-well UV platesin a reaction buffer with 50 mM Hepes, pH 7.5, 0.2 mg/mL BSA, 10 mM MgCl₂ and 2 mM DTT.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

Cells are seeded at 1,600 cells per well in 384-well white clear-bottom plates. Twenty-four hours after seeding, cells are treated with the compounds (eight dilution points, in duplicate, for each compound) and incubated for an additional 72 h at 37°C under a 5% CO₂ atmosphere. Cells are then lysed, and the ATP content in each well is determined using a thermostable firefly luciferase-based assay from Promega as a measure of cell viability. IC₅₀ values are calculated using the percentage of growth of treated cells versus the untreated control.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Paola Magnaghi, et al. Covalent and allosteric inhibitors of the ATPATP ase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Jul 28. doi: 10.1038/nchembio.1313. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9206 mL	9.6030 mL	19.2060 mL	48.0151 mL
	5 mM	0.3841 mL	1.9206 mL	3.8412 mL	9.6030 mL
	10 mM	0.1921 mL	0.9603 mL	1.9206 mL	4.8015 mL
	15 mM	0.1280 mL	0.6402 mL	1.2804 mL	3.2010 mL
	20 mM	0.0960 mL	0.4802 mL	0.9603 mL	2.4008 mL
	25 mM	0.0768 mL	0.3841 mL	0.7682 mL	1.9206 mL
	30 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6005 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

NMS-873

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Ubiquitination Compound Library

Endoplasmic Reticulum Stress Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) NMS-873

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NMS-873

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Ubiquitination Compound Library

Endoplasmic Reticulum Stress Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) NMS-873

Biological Activity

Chemical Information

Publications (19)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

NMS-873 Related Classifications

Cat. No.: HY-15713